<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16128">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896920</url>
  </required_header>
  <id_info>
    <org_study_id>P15-696</org_study_id>
    <nct_id>NCT02896920</nct_id>
  </id_info>
  <brief_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness</brief_title>
  <acronym>SOLACE</acronym>
  <official_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on Hidradenitis Suppurativa (HS) Burden of Illness and Health Care Resources Utilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses Humira's® real-life effectiveness in the management of dermatological
      manifestations of moderate to severe Hidradenitis Suppurativa (HS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>The HiSCR measure is defined as at least a 50% reduction in the Abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 52</measure>
    <time_frame>At Week 52</time_frame>
    <description>The HiSCR measure is defined as at least a 50% reduction in the Abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who experience worsening of HS by &gt;= 1 Hurley Stage in &gt;= 1 affected anatomic region</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This will be done by evaluating the Hurley Stage using the following description:
Stage I: Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).
Stage II: One or more widely separated recurrent abscesses with tract formation and cicatrization (scars).
Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who experience flare</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>It is defined as at least 25% increase in AN counts with a minimum increase of 2 relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days where participants experience HS flare-up</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>It is calculated from the day when flare is observed to the day prior to the observation that flare is no longer present. Of note, there could be multiple periods that flares are observed, in which case, the total days from the multiple periods will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health Utility Index Mark 3 (HUI3)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>This is a comprehensive system for measuring health status and health-related quality of life and for producing utility scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Assessment of HS (HS-PtGA)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The HSPtGA consists in one question that evaluates how one patient ranked the severity of HS at the time of the routine visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The HADS questionnaire includes 14 questions that evaluate the level of anxiety and depression an HS patient may experience associated with HS. A lower score indicates less severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The HSIA questionnaire includes 18 questions that evaluate the impacts an HS participant may experience associated with HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The HSSA questionnaire includes 9 questions that evaluate the symptoms an HS participant may experience associated with HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index (FSFI)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The FSFI questionnaire contains 19 questions that describe the female sexual function in 6 domains. The domains are: desire, arousal, lubrication, orgasm, satisfaction, and pain, which can both be evaluated individually and in their entirety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in International Index of Erectile Function (IIEF)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The IIEF contains 15 questions that were assigned in 5 domains of male sexuality: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0 (WPAI: SHP)</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>The WPAI: SHP evaluates four areas: percent work time missed due to HS, percent impairment while working due to HS, percent overall work impairment due to HS, and percent activity impairment due to HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health Care Resource Utilization (HCRU) associated with HS</measure>
    <time_frame>From Week 0 (baseline) to Week 52</time_frame>
    <description>This will be assessed using a descriptive questionnaire that aimed at measuring the patient's health care resource utilization and economic impact of HS.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hidradenitis Suppurativa (HS)</condition>
  <arm_group>
    <arm_group_label>Participants receiving adalimumab/ Humira®</arm_group_label>
    <description>Participants with HS for whom a change in treatment to Humira® is made by the treating physician</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with moderate or severe HS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a clinical diagnosis of moderate to severe HS according to the treating physician
             judgment

          -  Need a change in ongoing therapy for any reason, but not limited to inadequate
             response, intolerance, sub-optimal compliance, or patient preference. Patient will be
             approached to participate in the study after a decision to change patient's therapy
             for Humira® is made by the treating physician.

          -  Has provided written informed consent (Patient Authorization) for participation in
             the study

        Exclusion Criteria:

          -  Is participating in a clinical interventional study

          -  Was treated with Humira®, or any other biologic agents for HS prior to baseline visit

          -  Has any other active skin disease or condition that, in the opinion of the treating
             physician, prohibits the patient from participating in the study or obscures the
             assessment of the treatment of HS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Jean, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Daudrumez</last_name>
    <phone>514-832-7498</phone>
    <email>annie.daudrumez@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Labelle</last_name>
    <phone>514-832-7385</phone>
    <email>melanie.labelle@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152445</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152445, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152441</name>
      <address>
        <city>Bathurst</city>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152462</name>
      <address>
        <city>Brandon</city>
        <zip>R7A 0L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152462, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153833</name>
      <address>
        <city>Calgary</city>
        <zip>T2Z 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152448</name>
      <address>
        <city>Calgary</city>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152448, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153834</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153834, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152405</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152460</name>
      <address>
        <city>Edmonton</city>
        <zip>T6J 5E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152460, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153831</name>
      <address>
        <city>Edmonton</city>
        <zip>T6J 5E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153831, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152464</name>
      <address>
        <city>Fredericton</city>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152464, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153832</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153832, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152440</name>
      <address>
        <city>Kingston</city>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152440, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152406</name>
      <address>
        <city>Laval</city>
        <zip>H7N 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152406, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157923</name>
      <address>
        <city>London</city>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157923, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152436</name>
      <address>
        <city>Markham</city>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152436, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155339</name>
      <address>
        <city>Mississauga</city>
        <zip>L4Y 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155339, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152437</name>
      <address>
        <city>Montreal</city>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152458</name>
      <address>
        <city>North Bay</city>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152459</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152457</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152457, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152442</name>
      <address>
        <city>Pierrefonds</city>
        <zip>H8Z 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152447</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152456</name>
      <address>
        <city>Quebec</city>
        <zip>M5C1R6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152456, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152403</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152403, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152611</name>
      <address>
        <city>Saint-Jerome</city>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152611, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152408</name>
      <address>
        <city>St-Hyacinthe</city>
        <zip>J2S 6L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152408, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152435</name>
      <address>
        <city>St-John's</city>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152435, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152444</name>
      <address>
        <city>St. John's</city>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152444, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152438</name>
      <address>
        <city>St. John's</city>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152438, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152407</name>
      <address>
        <city>St. John's</city>
        <zip>A1E 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152407, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152404</name>
      <address>
        <city>Surrey</city>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152404, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157851</name>
      <address>
        <city>Toronto</city>
        <zip>M2 M4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157851, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152461</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157413</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157413, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152439</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152443</name>
      <address>
        <city>Verdun</city>
        <zip>H4G 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152443, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152446</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152446, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152463</name>
      <address>
        <city>Windsor</city>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153830</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153830, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153835</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153835, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>September 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Humira®</keyword>
  <keyword>Hidradenitis Suppurativa (HS)</keyword>
  <keyword>Canada</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
